Evidence mapPaperPMID 40128651Full record

Observational studyBMC infectious diseases2025

Modulation of RAAS receptors and miRNAs in COVID-19: implications for disease severity, immune response, and potential therapeutic targets.

Thais Freitas Barreto Fernandes, Jose Henrique Pilotto, Priscila Alves Cezar, Fernanda Heloise Côrtes, Mariza G Morgado, Carmem Beatriz W Giacoia-Gripp, Nathalia Beatriz Ramos De Sá, Andressa Da Silva Cazote, Agatha Freixinho Neves, Marcel De Souza Borges Quintana and 5 more

Abstract readObservational Study
In one paragraph

Observational study in BMC infectious diseases, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed, 1 pooled it
field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Article
  3. Review
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Thais Freitas Barreto FernandesLaboratório de AIDS e Imunologia Molecular, Instituto Oswaldo Cruz, FIOCRUZ, Rio de Janeiro, Brasil.
Jose Henrique PilottoLaboratório de AIDS e Imunologia Molecular, Instituto Oswaldo Cruz, FIOCRUZ, Rio de Janeiro, Brasil.
Priscila Alves CezarLaboratório de AIDS e Imunologia Molecular, Instituto Oswaldo Cruz, FIOCRUZ, Rio de Janeiro, Brasil.
Fernanda Heloise CôrtesLaboratório de AIDS e Imunologia Molecular, Instituto Oswaldo Cruz, FIOCRUZ, Rio de Janeiro, Brasil.
Mariza G MorgadoLaboratório de AIDS e Imunologia Molecular, Instituto Oswaldo Cruz, FIOCRUZ, Rio de Janeiro, Brasil.
Carmem Beatriz W Giacoia-GrippLaboratório de AIDS e Imunologia Molecular, Instituto Oswaldo Cruz, FIOCRUZ, Rio de Janeiro, Brasil.
Nathalia Beatriz Ramos De SáLaboratório de AIDS e Imunologia Molecular, Instituto Oswaldo Cruz, FIOCRUZ, Rio de Janeiro, Brasil.
Andressa Da Silva CazoteLaboratório de AIDS e Imunologia Molecular, Instituto Oswaldo Cruz, FIOCRUZ, Rio de Janeiro, Brasil.
Agatha Freixinho NevesLaboratório de AIDS e Imunologia Molecular, Instituto Oswaldo Cruz, FIOCRUZ, Rio de Janeiro, Brasil.
Marcel De Souza Borges QuintanaLaboratório de AIDS e Imunologia Molecular, Instituto Oswaldo Cruz, FIOCRUZ, Rio de Janeiro, Brasil.
Maria Pia Diniz RibeiroInstituto Nacional de Infectologia Evandro Chagas, FIOCRUZ, Rio de Janeiro, Brasil.
Sandra Wagner CardosoInstituto Nacional de Infectologia Evandro Chagas, FIOCRUZ, Rio de Janeiro, Brasil.
Valdiléa G VelosoInstituto Nacional de Infectologia Evandro Chagas, FIOCRUZ, Rio de Janeiro, Brasil.
Beatriz GrinsztejnInstituto Nacional de Infectologia Evandro Chagas, FIOCRUZ, Rio de Janeiro, Brasil.
Dalziza Victalina De AlmeidaLaboratório de AIDS e Imunologia Molecular, Instituto Oswaldo Cruz, FIOCRUZ, Rio de Janeiro, Brasil. dalziza@ioc.fiocruz.br.

Funding

Conselho Nacional de Desenvolvimento Científico e Tecnológico SEI-25380.001587/2020-20Fundação Carlos Chagas Filho de Amparo à Pesquisa do Estado do Rio de Janeiro E-26/200.946/2022Fundação Carlos Chagas Filho de Amparo à Pesquisa do Estado do Rio de Janeiro SEI-260003/013002/2021
6 · The paper itself

Abstract

The SARS-CoV-2 spike protein interacts with ACE2, a key receptor within the renin-angiotensin-aldosterone system (RAAS), which plays a critical role in maintaining vascular homeostasis, regulating blood pressure, and modulating inflammation. An observational study analyzed the gene expression profiles of RAAS receptors and associated miRNAs in 88 hospitalized COVID-19 patients and 20 healthy controls, comparing the acute and post-acute phases to assess their impact on disease severity and recovery. Our findings revealed an association between reduced MAS1 expression in both advanced age (P = 0.03) and the need for oxygen supplementation (P = 0.04). Additionally, reduced ACE expression was associated with worse mortality outcomes (P = 0.01). Notably, ACE2 and TMPRSS2 expression was significantly decreased (P < 0.0001) in individuals requiring oxygen supplementation and in those with diabetes mellitus during both the acute and post-COVID-19 phases, further highlighting the impact of these conditions on RAAS. The miRNA analysis revealed significant downregulation of miR-200c (P = 0.005), miR-let-7 (P = 0.01), and miR-122 (P = 0.03) in acute-phase COVID-19 patients. This dysregulation contributes to the inflammatory response and highlights the interaction between viral entry and immune regulation. These results underscore the significance of the ACE2/Ang-(1-7)/MAS1 axis in inflammation regulation and suggest that targeting this pathway may have therapeutic potential. Our study provides valuable insights into the molecular mechanisms of COVID-19 pathogenesis and identifies the modulation of RAAS receptors and miRNAs as promising biomarkers for disease severity and potential therapeutic interventions. CLINICAL TRIAL: Not applicable.

Indexed as

COVID-19MicroRNAsRenin-Angiotensin SystemAdultAgedAngiotensin-Converting Enzyme 2Case-Control StudiesFemaleHumansMaleMiddle AgedProto-Oncogene MasProto-Oncogene ProteinsSARS-CoV-2Serine EndopeptidasesSeverity of Illness IndexACE2 protein, humanAngiotensin-Converting Enzyme 2MAS1 protein, humanMicroRNAsProto-Oncogene MasProto-Oncogene ProteinsSerine EndopeptidasesTMPRSS2 protein, humanACE2COVID-19miRNARAASSARS-CoV-2

Identifiers

PMID40128651
PMCPMC11934810

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.